Nail Your Sales Interview with the 30/60/90 Day Sales Plan
If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.

Now you can nail your interview with the 30 60 90 Day Sales Plan template with Audio Coaching. This simple tool will help you knock the socks off your interviewer and bury your competition.

To get the details: Click Here

[Close Window]
Medical Sales Jobs Websites - the best Medical Sales Jobs | Laboratory Sales Jobs | Medical Device Sales Jobs

New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy

Aug 1st, 2009
by admin.

MELVILLE, N.Y.–(HSMN NewsFeed)–OSI Pharmaceuticals, Inc. (NASDAQ: OSIP ) today announced further results from the Phase III SATURN study showing that Tarceva(R) (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC…
Biopharmaceuticals, Oncology
OSI Pharmaceuticals, Genentech, Tarceva, erlotinib, lung cancer, NSCLC

New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy

Posted in: Medical Sales Jobs.

← U.S. Food and Drug Administration’s Arthritis Advisory Committee Confirms Date to Review XIAFLEX(TM) for the Treatment of Dupuytren’s Contracture
Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) →

0 Comments on “New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy”

Leave a Comment